Tandem Diabetes Care Announces Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Tandem Diabetes (TNDM) Tops Q4 EPS by 9c, Revenues Miss; Offers FY20 Revenue Guidance Above Consensus
February 24, 2020 4:11 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $108.4 million versus the consensus estimate of $109.22 million.
In comparing the fourth quarter of 2019 to the same period of 2018:
Worldwide pump shipments increased 21 percent to 19,602 pumps from 16,168 pumpsSales increased 42 percent to $108.4 million from $76.2 millionGross margin improved 1 point to 56 percent of sales... More